| Literature DB >> 32367275 |
Hiroki Kanno1, Hisamune Sakai2, Toru Hisaka2, Satoki Kojima2, Ryuta Midorikawa2, Shogo Fukutomi2, Yoriko Nomura2, Yuichi Goto2, Toshihiro Sato2, Munehiro Yoshitomi2, Ryuichi Kawahara2, Koji Okuda2.
Abstract
BACKGROUND: Reactive lymphoid hyperplasia (RLH) of the liver is a benign disorder. It is usually observed in the skin, orbit, thyroid, lung, breast, or gastrointestinal tract, but rarely in the liver. Since the first report of RLH of the liver in 1981, only 75 cases have been described in the past literature. Herein, we report a case of RLH of the liver in a patient with autoimmune hepatitis (AIH), which was misdiagnosed as hepatocellular carcinoma (HCC) preoperatively and resected laparoscopically. CASEEntities:
Keywords: Autoimmune hepatitis; Liver; Reactive lymphoid hyperplasia
Year: 2020 PMID: 32367275 PMCID: PMC7198675 DOI: 10.1186/s40792-020-00856-3
Source DB: PubMed Journal: Surg Case Rep ISSN: 2198-7793
Fig 1Abdominal ultrasound reveals a well-demarcated, homogenous, hypoechoic round nodule in segment 6 of the liver
Fig. 2On CT, the nodule is slightly enhanced in the arterial dominant phase (a). The lesion shows perinodular enhancement in the portal and delayed phases (b, c) (white arrow)
Fig. 3MRI demonstrates that the nodule shows well-defined low signal intensity in T1-weighted image (a), slightly high signal intensity in T2-weighted image (b), and strongly high signal intensity in diffusion-weighted image (c). Gd-EOB-DTPA-enhanced MRI reveals that the nodule is slightly enhanced in the arterial phase (d). The lesion shows perinodular enhancement in the portal phase (e) and a defect in hepatobiliary phase (f) (white arrowhead)
Fig. 4Pathological examination reveals that germinal centers are present and small lymphocytes and plasma cells are infiltrating the lesion (a). Marked lymphoid cell infiltration in the portal tracts was observed in the perinodular lesion (b)
Fig. 5Immunohistochemical staining reveals that the follicles are CD20-positive. The lymphocytes in the germinal centers are CD10-positive and Bcl-2-negative. The interfollicular area is composed of CD3-positive small T cells. Infiltrating plasma cells show a polyclonal expression of cellular immunoglobulin kappa and lambda chains
Clinicopathological features of reactive lymphoid hyperplasia of the liver
| Variables | Percentage | |
|---|---|---|
| Clinical characteristics | ||
| Age (ave, range) | 56.7 (15–85) | |
| Sex | ||
| Male | 5 | 6.6 |
| Female | 71 | 93.4 |
| Liver diseases | 35.5 | |
| Viral hepatitis B | 6 | |
| Viral hepatitis C | 2 | |
| Primary biliary cirrhosis | 14 | |
| Non-alcoholic steatohepatitis | 2 | |
| Autoimmune hepatitis | 3 | |
| Autoimmune disorders | 17.1 | |
| Chronic thyroiditis | 4 | |
| Sjögren’s syndrome | 3 | |
| Rheumatoid arthritis | 1 | |
| Takayasu disease | 1 | |
| Antiphospholipid syndrome | 1 | |
| CREST syndrome | 1 | |
| Immunodeficiency | 2 | |
| Malignant tumor | 27.6 | |
| Colon cancer | 6 | |
| Gastric cancer | 5 | |
| Renal cell carcinoma | 4 | |
| Cervical cancer | 1 | |
| Thyroid cancer | 1 | |
| Bile duct cancer | 1 | |
| Pancreatic cancer | 1 | |
| Ovarian cancer | 1 | |
| GIST | 1 | |
| Number of nodules | ||
| Solitary | 61 | 84.7 |
| Multiple | 11 | 15.3 |
| Nodule size (ave, range) (mm) | ||
| < 20 | 65 | 81.3 |
| ≥ 20 | 15 | 18.7 |
| Location | ||
| Rt. lobe | 39 | 62.9 |
| Lt. lobe | 15 | 24.2 |
| Caudate lobe | 3 | 4.8 |
| Bilobar | 5 | 8.1 |
| Preoperative diagnosis | ||
| Hepatocellular carcinoma | 31 | 53.4 |
| Cholangiocellular carcinoma | 4 | 6.9 |
| Metastatic | 12 | 20.7 |
| Malignant tumor | 7 | 12.1 |
| Others | 4 | 6.9 |
| Treatment | ||
| Operation | 63 | 82.9 |
| Biopsy | 8 | 10.5 |
| Transplantation | 3 | 3.9 |
| Others | 2 | 2.6 |
| Imaging findings (described) | ||
| US | ||
| Hypo | 39 | 51.3 |
| Iso | 1 | 1.3 |
| Unknown | 36 | 47.4 |
| CT (plain) | ||
| Low | 29 | 38.2 |
| Not detected | 2 | 2.6 |
| Unknown | 45 | 59.2 |
| CT (arterial phase) | ||
| Enhanced | 15 | 19.7 |
| Slightly enhanced | 15 | 19.7 |
| Perinodular enhancement | 9 | 11.8 |
| Not enhanced | 5 | 6.6 |
| Unknown | 32 | 42.1 |
| CT (portal or delay phase) | ||
| Washout | 23 | 30.3 |
| Perinodular enhancement | 8 | 10.5 |
| Not enhanced | 4 | 5.3 |
| Others | 5 | 6.6 |
| Unknown | 36 | 47.4 |
| MRI (T1WI) | ||
| Hypo | 42 | 55.3 |
| Slightly hypo | 4 | 5.3 |
| Unknown | 30 | 39.5 |
| MRI (T2WI) | ||
| Hyper | 38 | 50.0 |
| Slightly hyper | 5 | 6.6 |
| Iso | 3 | 3.9 |
| Unknown | 30 | 39.5 |
| MRI (arterial phase) | ||
| Enhanced | 13 | 17.1 |
| Slightly enhanced | 14 | 18.4 |
| Perinodular enhancement | 8 | 10.5 |
| Others | 3 | 3.9 |
| Unknown | 38 | 50.0 |
| MRI (portal or delay phase) | ||
| Washout | 19 | 25.0 |
| Perinodular enhancement | 8 | 10.5 |
| Others | 3 | 3.9 |
| Unknown | 46 | 60.5 |
| PET | ||
| Positive | 8 | 10.5 |
| SUV max (ave, range, | 4.9(3.4–6.7) | |
| Negative | 2 | 2.6 |
| Unknown | 66 | 86.8 |